The earnings call highlighted robust financial performance, successful growth in key segments like Molecular Diagnostics, and strategic M&A activities. However, challenges such as temporary headwinds in the Skeletal business, anticipated normalization in Breast Health growth, and external factors like IV fluid shortages were noted. Despite these challenges, the company's strong balance sheet and international growth prospects indicate a positive outlook.

Company Guidance

During the Hologic Q4 2024 earnings call, the company's executives provided guidance for fiscal 2025, projecting total revenue between $4.15 billion to $4.20 billion and non-GAAP EPS of $4.25 to $4.35. They expect organic revenue growth of approximately 4% at the midpoint, with diagnostics anticipated to grow mid-single digits, driven by BV/CV/TV assay and Biotheranostics BCI test. Molecular Diagnostics is projected to continue its strong performance, while the introduction of new products like the Genius digital cytology in the U.S. represents additional growth opportunities. Headwinds such as the skeletal business stop ship, respiratory season variability, and IV fluid shortages are expected to impact the first half of fiscal 2025. However, margin expansion is anticipated, with gross margins expected around 60% in Q1, gradually improving by 50 basis points throughout the year, alongside operating margins projected to increase by 50 to 100 basis points over the same period. The company plans to continue balancing M&A and share repurchase strategies, with a new $250 million accelerated share repurchase program set to commence.

Strong Revenue and EPS Performance

Total revenue for Q4 was $987.9 million, with non-GAAP EPS at $1.01. For the full fiscal year 2024, revenue reached $4.03 billion and EPS was $4.08, showcasing solid financial performance.

Growth in Molecular Diagnostics

The Molecular Diagnostics segment grew by 9% excluding COVID for the full year, driven by strong Panther utilization and assay adoption.

Successful M&A Strategy

The company completed tuck-in acquisitions of Endomagnetics and Gynasonix, aligning with their M&A strategy to enhance their global portfolio.

Strong Balance Sheet and Capital Allocation

In 2024, Hologic repurchased 11.2 million shares for $808 million and announced a new $250 million accelerated share repurchase program, demonstrating effective capital management.

International Growth Potential

The international business is nearly 50% larger compared to 2019, with significant growth prospects as the company continues to expand its global footprint.

---

Hologic (HOLX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HOLX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jan 29, 2025	2025 (Q1)	1.01 / -	0.98	―	―	―
Nov 04, 2024	2024 (Q4)	1.01 / 1.01	0.89	13.48% (+0.12)
Jul 29, 2024	2024 (Q3)	1.02 / 1.06	0.93	13.98% (+0.13)
May 02, 2024	2024 (Q2)	0.98 / 1.03	1.06	-2.83% (-0.03)
Feb 01, 2024	2024 (Q1)	0.95 / 0.98	1.07	-8.41% (-0.09)
Nov 09, 2023	2023 (Q4)	0.84 / 0.89	0.82	8.54% (+0.07)
Jul 31, 2023	2023 (Q3)	0.89 / 0.93	0.95	-2.11% (-0.02)
May 01, 2023	2023 (Q2)	0.88 / 1.06	2.07	-48.79% (-1.01)
Feb 01, 2023	2023 (Q1)	0.91 / 1.07	2.17	-50.69% (-1.10)
Oct 31, 2022	2022 (Q4)	0.62 / 0.82	1.61	-49.07% (-0.79)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

HOLX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2024	$83.72	$78.80	-5.88%
Jul 29, 2024	$79.64	$82.51	+3.60%
May 02, 2024	$75.91	$76.54	+0.83%
Feb 01, 2024	$74.41	$72.44	-2.65%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---